London, UK, August 19, 2014 – Medisico plc (‘Medisico’), the life science, medical device and technology company with a number of subsidiary companies operating in the aesthetics, medical devices, medical treatment, surgical and laser treatment marketplaces, today announces that Medisico will list on the GXG First Quote Market. The listing will be effective today, August 19.
The GXG First Quote Market is set up for smaller companies to benefit from a market quote and provides the opportunity for compliance with rules and regulations of the public marketplace. Medisico will benefit from having its share price and company information displayed on the GXG Markets website where appropriate, and will have their share price and charting shown on Bloomberg’s terminals, website and smartphone investor apps. Medisico will also benefit from having its regulatory news and trading updates placed to both the market and secondary information providers that include Thomson Reuters.
“Our investor base has widened considerably from a group of investors from our start-up phase, where personal contacts have contributed nearly £0.5 million to our initial capital base. The GXG First Quote listing is the next stage of our programme to grow Medisico into the most significant organisation in its operating environment. This listing is essential for Medisico’s expansion plans and the launch of our subsidiary companies,” said Stephen Soos, CEO, Medisico. “Combining our technology, intellectual property management, dedication and skill has provided the company with a great set of opportunities to expand into a variety of markets.”
Information about Medisico
Rebranded in the second quarter of 2014, Medisico has evolved into a group with four subsidiaries, Medisico Aesthetic Medicine Ltd, an aesthetic medical division, Medisico Clinics Ltd, a clinical division that will operate aesthetic treatments, minor surgery and primary care treatments, Medisico Academy Ltd, which will concentrate on education and training as well as delivering the R&D from their IP, and Medisico General Medicine Ltd, a general medical division which will undertake a programme of clinical trials. The first of these studies will be on ulcer and ulcer cure, and vaginal laxity treatment. Each of these subsidiaries has a separate management team reporting to the Medisico board, thus allowing each to focus on specific market segments.
In addition, Medisico plans to launch other wholly-owned subsidiaries in 2015 as well as part-owned subsidiaries in Europe, South Africa, Australasia and the Middle East in conjunction with equally driven and socially responsible partners in those regions.
About Medisico
Medisico plc is a life sciences company delivering medical and aesthetic treatments developed from proprietary IP and technologies. The therapies and treatments are delivered via highly trained clinical partners. Medisico plc has launched 4 subsidiaries, with another set of international subsidiaries to follow. Medisico is operating from London and Nottinghamshire, UK. Currently 11 of its directors in Medisico and its subsidiaries work for the business with a substantial number working for their partners.
Help employers find you! Check out all the jobs and post your resume.
